Using RNA interference technology, scientists have discovered a network of genes that could serve as new therapeutic targets for Parkinson's disease as well as other diseases characterized by mitochondrial damage.
Amidst a challenging R&D environment, Atlanta-based Biota Pharmaceuticals has dumped its preclinical antibiotics program, saying that it will continue to seek out licensing agreements and other deals to advance the development of its candidates.
Eli Lilly and the nonprofit Project A.L.S. are teaming up to boost the pipeline of potential drugs for amyotrophic lateral sclerosis (ALS), also known as Lou Gehrig' disease.
A DNA vaccine developed by Blue Bell, PA-based Inovio Pharmaceuticals induced robust and durable immune responses against the deadly MERS coronavirus in a preclinical model.
Austrian researchers have discovered a compound that may be able to activate a protein in the body to trigger fat burning.
The antidote for Alzheimer's may be hidden in two common herbs. A study conducted at Saint Louis University found that enhanced extracts derived from antioxidants in spearmint and rosemary improved learning and memory in mice.
Investigators at MIT may have found the key to designing the next generation of antibiotics--a toxin called SocAB that blocks DNA replication and inhibits bacterial growth.
Three-dimensional kidney structures created for the first time in a laboratory by scientists at the Salk Institute for Biological Studies could provide a new possibility for developing drugs that treat kidney disease and restore kidney function.
Oxford University scientists are teaming up with London-based MRC Technology, a tech transfer nonprofit, to screen selective and potent potassium channel activators that could be formulated into new therapies for migraine relief.
Canada's Tekmira Pharmaceuticals ($TKMR) has unveiled new data showing that its antiviral RNA interference therapeutics were effective at abolishing Ebola and Marburg viruses in preclinical studies when treatment was delayed.
A cellular pathway interaction that plays a role in repairing serious injuries may also be a promising target for preventing the spread of a deadly type of brain cancer, according to a new study.
By targeting a family of proteins on the surface of certain cells, scientists have been able to halt and reverse tissue scarring in liver, kidneys and lungs in mice.
Boehringer Ingelheim has chosen an antibody therapeutic candidate discovered by Rockville, MD-based MacroGenics for preclinical development.
The White House's Office of Management and Budget released a new report that sheds light on how the 16-day federal government shutdown in October impacted scientific research.
A new public health partnership called the Global Health Innovative Technology Fund is doling out $5.7 million in grants to 6 programs across the globe to boost research and development of promising vaccines against malaria, tuberculosis and Chagas disease.
The number of failures in the Alzheimer's drug research field has been piling up disproportionately compared to successes in recent years, and the New York Academy of Sciences is hoping to change that by proposing a more streamlined, efficient path for Alzheimer's drug development.
A person's genetics are responsible for a decline in brain function in normal aging, according to a new study conducted by researchers at the Texas Biomedical Research Institute in San Antonio and Yale University.
Scientists at the Cambridge, MA, startup Sage Therapeutics have discovered an innate mechanism that indirectly influences a key receptor linked to a number of neurologic and psychiatric disorders, including Alzheimer's, schizophrenia, autism and depression.
NIH has issued an updated fact sheet on the impact of federal sequestration, which totaled nearly $1.6 billion in cuts this year.
Australian Prana Biotechnology has published new data showing its metal-transporting compound PBT2 reversed memory and learning loss associated with the aging process in elderly mice.